Table 2. Maximum dose of valproic acid (VPA) received during the entire treatment perioda.
|
Maximum VPA dose (mg kg −1day−1)
|
||||
|---|---|---|---|---|
|
(First cohort, N=10)
|
(Second cohort, N=19)
|
|||
| 10 | 30 | 60 | 90 | |
| Number of patients | 3 | 7 | 15 | 4 |
| Median duration at maximum dose (days) | 8 | 16 | 26 | 19 |
| Temporary suspension (number of patients) | 1 | 1 | 4 | 3 |
| Dose reduction (number of patients) | 1 | 4 | 5 | 3 |
| Stopped VPA in advance (number of patients)b | 3 | 7 | 6 | 2 |
a
On 29 patients who actually started VPA assumption.
b
Five serious adverse events, 1 non-compliance, 12 treatment failures.